Although IL-6/IL-6R-inhibiting compounds are in clinical development for various cancers,67 there is evidence that vaccination-based immunotherapy depends on IL-6 signaling in TAMs for optimal treatment efficacy.68 This evidence concerns the gene IL6R and cancer.